Dr. Aberger Discusses a Cost Analysis of Testicular Self-Examinations

Video

Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.

Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.

The United States Preventative Services Task Force (USPSTF) came out with a recommendation against testicular self-examinations in asymptomatic men, and the recommendation has been revisited several times. Aberger and colleagues went back and found that no cost analysis was performed.

In this analysis, it was demonstrated that 322 clinic evaluations could be performed for the same cost as one missed advanced stage cancer. It was then estimated that, based on the SEER database, approximately 300,000 benign office visits could have been performed at the same cost of all metastatic prostate cancer treated in 2013.

The main takeaway of this analysis, Aberger says, is that the fiscal ramifications of the USPSTF recommendation should be considered.

<<<

View more from the 2014 AUA Annual Meeting

Related Videos
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center